Risk of dilution from new share issuance and stock acquisition rights
First written in FY2020. 23 of 25 entries say "Materialised", first in FY2021-Q1. Latest entry: FY2026.
StemRIM moved to the "Worse" side of this theme in 2020, the same year as the typical company in this theme.
The whole theme swung hardest in 2018: 9 of 9 companies on the "Worse" side.
0 other companies' latest entry also says "Other".
- FY2026Additional issuance of stock acquisition rightsAnnual report
「31 types of stock acquisition rights (6,068,000 common shares)」
Following the issue of additional stock acquisition rights, the number of potential shares increased from 28 types and 5,455,000 shares at the end of the previous fiscal year to 31 types and 6,068,000 shares, increasing the potential for future dilution of share value. - FY2026-H1MaterialisedAnnual report
「(Note) Increase resulting from the issuance of new shares as restricted stock compensation.」
On 10 December 2025, 545,000 shares were issued as restricted stock compensation, further realizing the existing risk of dilution of equity value. - FY2025MaterialisedAnnual report
「The increase of 613,000 in the number of issued common shares comprises 475,000 shares allocated as restricted stock compensation and an increase of 138,000 shares resulting from the exercise of stock options.」
During the fiscal year, 475,000 restricted shares were issued and stock options for 138,000 shares were exercised, additionally realizing the potential for dilution of equity value. - FY2025-H1MaterialisedAnnual report
「Of the issued shares, 1,269,000 were issued as restricted stock compensation through an in-kind contribution of monetary compensation receivables of ¥750.512 million.」
During the interim accounting period, 138,000 shares were issued upon the exercise of share acquisition rights, and an additional 475,000 shares were issued as restricted stock compensation, further realizing the dilution of equity value. - FY2024MaterialisedAnnual report
「The increase of 645,600 in the number of issued common shares comprises 433,000 shares allocated as restricted stock compensation and an increase of 212,600 shares resulting from the exercise of stock options.」
The issuance of 433,000 restricted shares and the exercise of stock options for 212,600 shares additionally realized the potential for dilution of equity value. - FY2024-Q3MaterialisedAnnual report
「1 February 2024 to 30 April 2024 (Note) 38,400 61,508,200 10,449 218,071 10,449 9,214,003 (Note) Increase resulting from the exercise of share acquisition rights.」
During the third quarter, 38,400 shares were issued upon the exercise of share acquisition rights, additionally realizing the potential for dilution of equity value. - FY2024-Q2MaterialisedAnnual report
「1 November 2023–31 January 2024 15,000 61,469,800 2,250 207,622 2,250 9,203,554 (Note) 2. Increase due to the exercise of stock acquisition rights.」
15,000 shares were additionally issued upon the exercise of share acquisition rights, further realizing the previously disclosed potential for dilution of equity value. - FY2024-Q1MaterialisedAnnual report
「1 August 2023–31 October 2023 (Note) 144,200 61,021,800 35,905 51,657 35,905 9,047,589 (Note) Increase due to the exercise of stock acquisition rights.」
During the first quarter, 144,200 shares were issued through the exercise of stock acquisition rights, additionally realizing the previously disclosed potential dilution of shareholder value. - FY2023MaterialisedAnnual report
「8 December 2022–28 July 2023 938,000 60,877,600 80,139 214,326 80,139 8,813,110」
During the current fiscal year, 938,000 shares were issued through the exercise of stock acquisition rights, additionally realizing the potential dilution of shareholder value. - FY2023-Q3MaterialisedAnnual report
「1 February 2023–30 April 2023 (Note) 651,400 60,647,000 19,655 159,571 19,655 8,758,355 (Note) Increase due to the exercise of stock acquisition rights.」
An additional 651,400 shares were issued through the exercise of stock acquisition rights, additionally realizing the previously disclosed potential dilution of shareholder value. - FY2023-Q2MaterialisedAnnual report
「1 November 2022–31 January 2023 56,000 59,995,600 5,729 139,916 5,729 8,738,699 (Note) Increase due to the exercise of stock acquisition rights.」
An additional 56,000 shares were issued through the exercise of stock acquisition rights, further realizing the potential dilution of shareholder value. - FY2023-Q1MaterialisedAnnual report
「1 August 2022–31 October 2022 (Note) 257,200 59,659,600 61,051 137,367 61,051 10,681,224 (Note) Increase due to the exercise of stock acquisition rights.」
During the first quarter, 257,200 shares were issued through the exercise of stock acquisition rights, additionally realizing the potential dilution of shareholder value. - FY2022MaterialisedAnnual report
「10 December 2021–31 July 2022 357,300 59,402,400 45,577 76,315 45,577 10,620,172 (Note) 7. Increase due to the exercise of stock acquisition rights.」
An additional 357,300 shares were issued through the exercise of stock acquisition rights, additionally realizing the previously disclosed potential dilution of shareholder value. - FY2022-Q3MaterialisedAnnual report
「1 February 2022–30 April 2022 (Note) 30,000 59,342,700 4,500 66,876 4,500 10,610,732 (Note) Increase due to the exercise of stock acquisition rights.」
During the third quarter, an additional 30,000 shares were issued through the exercise of stock acquisition rights, additionally realizing the previously disclosed potential dilution of shareholder value. - FY2022-Q2MaterialisedAnnual report
「1 November 2021–31 January 2022 267,600 59,312,700 31,637 62,376 31,637 10,606,232 (Note) Increase due to the exercise of stock acquisition rights.」
During the cumulative second quarter, an additional 267,600 shares were issued through the exercise of stock acquisition rights, bringing the total number of issued shares to 59,312,700. The potential dilution of shareholder value was additionally realized. - FY2022-Q1MaterialisedAnnual report
「1 August 2021–31 October 2021 (Note) 112,500 58,964,100 15,515 47,939 15,515 10,515,922 (Note) Increase due to the exercise of stock acquisition rights.」
An additional 112,500 shares were issued through the exercise of stock acquisition rights, realizing the potential dilution of shareholder value. In addition, the issuance of 81,000 restricted shares had been completed after the filing date. - FY2021MaterialisedAnnual report
「2 December 2020–31 July 2021 1,239,300 58,851,600 15,526 32,424 15,526 10,500,407 (Note) Increase due to the exercise of stock acquisition rights.」
During the current fiscal year, 1,239,300 shares were issued through the exercise of stock acquisition rights, additionally realizing the potential dilution of shareholder value. - FY2021-Q3MaterialisedAnnual report
「1 February 2021–30 April 2021 (Note) 426,000 58,802,700 1,617 26,416 1,617 10,494,400 (Note) Increase due to the exercise of stock acquisition rights.」
Through the exercise of stock acquisition rights, 426,000 shares were issued between February and April 2021, additionally realizing the potential dilution of shareholder value. - FY2021-Q2MaterialisedAnnual report
「1 November 2020–31 January 2021 (Note) 2 764,400 58,376,700 7,902 24,799 7,902 10,492,782」
Through the exercise of stock acquisition rights, 764,400 shares were issued between November 2020 and January 2021, additionally realizing the potential dilution of shareholder value. - FY2021-Q1MaterialisedAnnual report
「1 August 2020–31 October 2020 (Note) 822,900 57,612,300 40,622 89,910 40,622 10,411,867 (Note) Increase due to the exercise of stock acquisition rights.」
During the first quarter, 822,900 shares were issued through the exercise of stock acquisition rights, partially realizing the previously disclosed potential dilution of shareholder value. - FY2020First statedAnnual report
「As of the end of the month preceding the filing date, the Company's total number of issued shares was 57,026 thousand. If all issued stock acquisition rights are exercised, 6,897 thousand new shares will be issued, potentially diluting the Company's per-share value.」
The potential issuance of an additional 6,897 thousand shares upon full exercise of the issued stock acquisition rights has been disclosed as a risk of dilution of shareholder value.